Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Y5LX
|
|||
Former ID |
DNC010611
|
|||
Drug Name |
4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
|
|||
Synonyms |
CHEMBL1085896; 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
![]() |
Download2D MOL |
||
Formula |
C14H19N3
|
|||
Canonical SMILES |
CCCC1=CC(=NC(=N1)C#N)C2CCCCC2
|
|||
InChI |
1S/C14H19N3/c1-2-6-12-9-13(17-14(10-15)16-12)11-7-4-3-5-8-11/h9,11H,2-8H2,1H3
|
|||
InChIKey |
WGTHPYHNMKDPLN-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cathepsin K (CTSK) | Target Info | Inhibitor | [1] |
KEGG Pathway | Lysosome | |||
Osteoclast differentiation | ||||
Toll-like receptor signaling pathway | ||||
Rheumatoid arthritis | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
RANKL Signaling Pathway | ||||
IL2 Signaling Pathway | ||||
Reactome | Collagen degradation | |||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
Trafficking and processing of endosomal TLR | ||||
MHC class II antigen presentation | ||||
WikiPathways | RANKL/RANK Signaling Pathway | |||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.